These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37468622)

  • 1. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming.
    Juul NH; Yoon JK; Martinez MC; Rishi N; Kazadaeva YI; Morri M; Neff NF; Trope WL; Shrager JB; Sinha R; Desai TJ
    Nature; 2023 Jul; 619(7971):860-867. PubMed ID: 37468622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.
    Yang M; Shen H; Flodby P; Koss MD; Bassiouni R; Liu Y; Jashashvili T; Neely A; Ogbolu E; Castillo J; Stueve TR; Mullen DJ; Ryan AL; Carpten J; Castaldi A; Wallace WD; Zhou B; Borok Z; Marconett CN
    Cell Rep; 2023 Dec; 42(12):113286. PubMed ID: 37995179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alveolar progenitor and stem cells in lung development, renewal and cancer.
    Desai TJ; Brownfield DG; Krasnow MA
    Nature; 2014 Mar; 507(7491):190-4. PubMed ID: 24499815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
    Cho HC; Lai CY; Shao LE; Yu J
    Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
    Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
    Cancer Discov; 2024 Feb; 14(2):308-325. PubMed ID: 37931288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage lung cancer is driven by a transitional cell state dependent on a KRAS-ITGA3-SRC axis.
    Moye AL; Dost AF; Ietswaart R; Sengupta S; Ya V; Aluya C; Fahey CG; Louie SM; Paschini M; Kim CF
    EMBO J; 2024 Jul; 43(14):2843-2861. PubMed ID: 38755258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
    Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
    Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alveolar progenitor cells and the origin of lung cancer.
    Sainz de Aja J; Dost AFM; Kim CF
    J Intern Med; 2021 May; 289(5):629-635. PubMed ID: 33340175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
    Han G; Sinjab A; Rahal Z; Lynch AM; Treekitkarnmongkol W; Liu Y; Serrano AG; Feng J; Liang K; Khan K; Lu W; Hernandez SD; Liu Y; Cao X; Dai E; Pei G; Hu J; Abaya C; Gomez-Bolanos LI; Peng F; Chen M; Parra ER; Cascone T; Sepesi B; Moghaddam SJ; Scheet P; Negrao MV; Heymach JV; Li M; Dubinett SM; Stevenson CS; Spira AE; Fujimoto J; Solis LM; Wistuba II; Chen J; Wang L; Kadara H
    Nature; 2024 Mar; 627(8004):656-663. PubMed ID: 38418883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS
    Pribluda A; Daemen A; Lima AN; Wang X; Hafner M; Poon C; Modrusan Z; Katakam AK; Foreman O; Eastham J; Hung J; Haley B; Garcia JT; Jackson EL; Junttila MR
    Elife; 2022 Aug; 11():. PubMed ID: 35983994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of Mutant
    Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
    Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
    Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
    Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IκB Kinase α Is Required for Development and Progression of
    Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
    Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
    Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation.
    Regala RP; Justilien V; Walsh MP; Weems C; Khoor A; Murray NR; Fields AP
    PLoS One; 2011; 6(10):e26439. PubMed ID: 22022614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
    Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
    PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.